In total, 158 recurrent and stage IV NSCLC patients receiving osimertinib as sequential treatment were included for final analysis, with all of them harboring acquired T790M mutation after having experienced drug resistance to a first-line EGFR-TKI therapy that involved gefitinib, erlotinib, and afatinib (Figure S1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.